Nanjing Anji Biotechnology Co. Ltd. has patented micropeptides regulating cholesterol metabolism and thus reported to be useful for the treatment of obesity, atherosclerosis, age-related macular degeneration, hyperlipidemia, fatty liver, liver fibrosis, liver cancer and coronary heart disease, among others.